HCPLive 5 Stories in Under 5: Week of 05/11

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!Interested in a more traditional, text rundown? Check out the HCPFive!Top 5 Healthcare Headlines for May 5- 11, 2025:FDA Accepts Sparsentan (Filspari) sNDA for Focal Segmental GlomerulosclerosisThe FDA will review Travere Therapeutics’ application for full approval of sparsentan in FSGS, with an advisory committee meeting planned ahead of a January 2026 decision.FDA Accepts BioCryst’s NDA for Berotralstat Oral Granules in Children With HAEThe FDA is evaluating berotralstat oral granules for pediatric hereditary angioedema, which could become the first oral preventive therapy for children under 12.SURMOUNT-5: Tirzepatide (Zepbound) Proves Benefit over Semaglutide (Wegovy) for ObesityTirzepatide demonstrated superior weight loss outcomes compared with semaglutide in the SURMOUNT-5 trial for patients with obesity.Crinecerfont Reduces Steroid Use for Pediatric CAH in Phase 3 AnalysisCrinecerfont lowered steroid requirements while maintaining hormone control in children with classic congenital adrenal hyperplasia, regardless of baseline characteristics.Type 1 Diabetes Diagnosed in Adulthood Heightens Cardiovascular RiskAdults diagnosed with type 1 diabetes face increased cardiovascular and all-cause mortality risks, regardless of age at diagnosis, according to long-term national data.